BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yoshida A, Hayashi N, Suzuki K, Takimoto M, Nakamura S, Yamauchi H. Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer. J Surg Oncol 2017;116:1021-8. [DOI: 10.1002/jso.24762] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Yoshida A, Hayashi N. Reply to Kadri Altundag. J Surg Oncol 2018;117:329. [PMID: 28968921 DOI: 10.1002/jso.24838] [Reference Citation Analysis]
2 Pizzuti L, Krasniqi E, Sperduti I, Barba M, Gamucci T, Mauri M, Veltri EM, Meattini I, Berardi R, Di Lisa FS, Natoli C, Pistelli M, Iezzi L, Risi E, D’ostilio N, Tomao S, Ficorella C, Cannita K, Riccardi F, Cassano A, Bria E, Fabbri MA, Mazzotta M, Barchiesi G, Botticelli A, D’auria G, Ceribelli A, Michelotti A, Russo A, Salimbeni BT, Sarobba G, Giotta F, Paris I, Saltarelli R, Marinelli D, Corsi D, Capomolla EM, Sini V, Moscetti L, Mentuccia L, Tonini G, Raffaele M, Marchetti L, Minelli M, Ruggeri EM, Scavina P, Bacciu O, Salesi N, Livi L, Tinari N, Grassadonia A, Fedele Scinto A, Rossi R, Valerio MR, Landucci E, Stani S, Fratini B, Maugeri-saccà M, De Tursi M, Maione A, Santini D, Orlandi A, Lorusso V, Cortesi E, Sanguineti G, Pinnarò P, Cappuzzo F, Landi L, Botti C, Tomao F, Cappelli S, Bon G, Pelle F, Cavicchi F, Fiorio E, Foglietta J, Scagnoli S, Marchetti P, Ciliberto G, Vici P. PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting. Ther Adv Med Oncol 2021;13:175883592110598. [DOI: 10.1177/17588359211059873] [Reference Citation Analysis]
3 Gambert P, Lallemant C, Andre JL, Athias A, Bourquard R, Pierson M, Padieu P. Cholesterol content of serum lipoprotein fractions in children maintained on chronic hemodialysis. Clin Chim Acta. 1981;110:295-300. [PMID: 7226533 DOI: 10.3390/cancers12040821] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
4 Cirauqui B, Morán T, Estival A, Quiroga V, Etxaniz O, Balana C, Navarro M, Villà S, Ballester R, Margelí M. Breast Cancer Patient with Li-Fraumeni Syndrome: A Case Report Highlighting the Importance of Multidisciplinary Management. Case Rep Oncol 2020;13:130-8. [PMID: 32231534 DOI: 10.1159/000505684] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Bourrier C, Pierga JY, Xuereb L, Salaun H, Proudhon C, Speicher MR, Belic J, Heitzer E, Lockhart BP, Guigal-Stephan N. Shallow Whole-Genome Sequencing from Plasma Identifies FGFR1 Amplified Breast Cancers and Predicts Overall Survival. Cancers (Basel) 2020;12:E1481. [PMID: 32517171 DOI: 10.3390/cancers12061481] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Li C, Fan H, Xiang Q, Xu L, Zhang Z, Liu Q, Zhang T, Ling J, Zhou Y, Zhao X, Cui Y. Prognostic value of receptor status conversion following neoadjuvant chemotherapy in breast cancer patients: a systematic review and meta-analysis. Breast Cancer Res Treat 2019;178:497-504. [PMID: 31471838 DOI: 10.1007/s10549-019-05421-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
7 D'Amico S, Krasnowska EK, Manni I, Toietta G, Baldari S, Piaggio G, Ranalli M, Gambacurta A, Vernieri C, Di Giacinto F, Bernassola F, de Braud F, Lucibello M. DHA Affects Microtubule Dynamics Through Reduction of Phospho-TCTP Levels and Enhances the Antiproliferative Effect of T-DM1 in Trastuzumab-Resistant HER2-Positive Breast Cancer Cell Lines. Cells 2020;9:E1260. [PMID: 32438775 DOI: 10.3390/cells9051260] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
8 Li X, Wang M, Wang M, Yu X, Guo J, Sun T, Yao L, Zhang Q, Xu Y. Predictive and Prognostic Roles of Pathological Indicators for Patients with Breast Cancer on Neoadjuvant Chemotherapy. J Breast Cancer 2019;22:497-521. [PMID: 31897326 DOI: 10.4048/jbc.2019.22.e49] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
9 Wetzel CL, Sutton TL, Gardiner S, Farinola M, Johnson N, Garreau JR. Loss of HER2-positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes. J Surg Oncol 2021. [PMID: 34416025 DOI: 10.1002/jso.26646] [Reference Citation Analysis]
10 Schneider J, Lee HJ, Nam SJ, Lee SJ, Jung JH, Jung SH, Lim ST, Jeon YW, Gwak H. Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients. J Breast Cancer 2020;23:259-67. [PMID: 32595988 DOI: 10.4048/jbc.2020.23.e34] [Reference Citation Analysis]
11 Chen Y, Liu X, Yu K, Sun X, Xu S, Qiu P, Lv Z, Zhang X, Guo A, Xu Y. Impact of hormone receptor, HER2, and Ki-67 status conversions on survival after neoadjuvant chemotherapy in breast cancer patients: a retrospective study. Ann Transl Med 2022;10:93. [PMID: 35282081 DOI: 10.21037/atm-21-6924] [Reference Citation Analysis]
12 Del Prete S, Caraglia M, Luce A, Montella L, Galizia G, Sperlongano P, Cennamo G, Lieto E, Capasso E, Fiorentino O, Aliberti M, Auricchio A, Iodice P, Addeo R. Clinical and pathological factors predictive of response to neoadjuvant chemotherapy in breast cancer: A single center experience. Oncol Lett 2019;18:3873-9. [PMID: 31516598 DOI: 10.3892/ol.2019.10729] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
13 Zhu Y, Zhang Y, Ma Y, Li H, Liu A, Han P, Yin L, Lv N, Li Z, Lu H, Liu P, Ye Z. Cone-beam breast CT features associated with HER2/neu overexpression in patients with primary breast cancer. Eur Radiol 2020;30:2731-9. [PMID: 31900700 DOI: 10.1007/s00330-019-06587-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Li A, Keck JM, Parmar S, Patterson J, Labrie M, Creason AL, Johnson BE, Downey M, Thomas G, Beadling C, Heiser LM, Kolodzie A, Guimaraes AR, Corless CL, Gray JW, Mills GB, Bergan RC, Mitri ZI. Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics. NPJ Precis Oncol 2021;5:28. [PMID: 33772089 DOI: 10.1038/s41698-021-00165-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Hayashi N, Yagata H, Tsugawa K, Kajiura Y, Yoshida A, Takei J, Yamauchi H, Nakamura S. Response and Prognosis of Docetaxel and Cyclophosphamide as Neoadjuvant Chemotherapy in ER+ HER2- Breast Cancer: A Prospective Phase II Study. Clin Breast Cancer 2020;20:462-8. [PMID: 33046356 DOI: 10.1016/j.clbc.2020.09.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
16 Jeong YH, Hong SA, Ahn HS, Ahn SK, Kim MK. Clinicopathologic factors affecting discrepancies in HER2 overexpression between core needle biopsy and surgical biopsy in breast cancer patients according to neoadjuvant treatment or not. J Cancer 2021;12:4722-8. [PMID: 34149935 DOI: 10.7150/jca.59419] [Reference Citation Analysis]
17 Yu J, Li NL. Loss of human epidermal receptor-2 in human epidermal receptor-2+ breast cancer after neoadjuvant treatment: A case report. World J Clin Cases 2022; 10(17): 5923-5928 [DOI: 10.12998/wjcc.v10.i17.5923] [Reference Citation Analysis]
18 Skálová H, Hájková N, Majerová B, Bártů M, Povýšil C, Tichá I. Impact of chemotherapy on the expression of claudins and cadherins in invasive breast cancer. Exp Ther Med 2019;18:3014-24. [PMID: 31572543 DOI: 10.3892/etm.2019.7930] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
19 Cuypers E, Claes BSR, Biemans R, Lieuwes NG, Glunde K, Dubois L, Heeren RMA. 'On the Spot' Digital Pathology of Breast Cancer Based on Single-Cell Mass Spectrometry Imaging. Anal Chem 2022. [PMID: 35413180 DOI: 10.1021/acs.analchem.1c05238] [Reference Citation Analysis]
20 Avan Z, Biabani Ardakani J, Talebpour Amiri F, Abedi SM, Hosseinimehr SJ. The Potential Usefulness of 99m Tc-HYNIC-(Ser) 3 -LTVPWY Peptide for Predicting HER2 Status Alteration After Chemotherapy in Ovarian Tumor-Bearing Mice. Cancer Biotherapy and Radiopharmaceuticals. [DOI: 10.1089/cbr.2020.4004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Candás G, García A, Ocampo MD, Korbenfeld E, Vuoto HD, Isetta J, Cogorno L, Zimmermann AG, Sigal M, Acevedo S, Berwart J, Naveira M, Bemi A, Uriburu JL. Impact of immunohistochemical profile changes following neoadjuvant therapy in the treatment of breast cancer. Ecancermedicalscience 2021;15:1162. [PMID: 33680076 DOI: 10.3332/ecancer.2021.1162] [Reference Citation Analysis]
22 Al-Saleh K, Salah T, Arafah M, Husain S, Al-Rikabi A, Abd El-Aziz N. Prognostic significance of estrogen, progesterone and HER2 receptors' status conversion following neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from a tertiary Cancer Center in Saudi Arabia. PLoS One 2021;16:e0247802. [PMID: 33667252 DOI: 10.1371/journal.pone.0247802] [Reference Citation Analysis]
23 Wang L, Jiang Q, He MY, Shen P. HER2 changes to positive after neoadjuvant chemotherapy in breast cancer: A case report and literature review . World J Clin Cases 2022; 10(1): 260-267 [DOI: 10.12998/wjcc.v10.i1.260] [Reference Citation Analysis]
24 Al-Zeheimi N, Adham SA. Modeling Neoadjuvant chemotherapy resistance in vitro increased NRP-1 and HER2 expression and converted MCF7 breast cancer subtype. Br J Pharmacol 2020;177:2024-41. [PMID: 31883395 DOI: 10.1111/bph.14966] [Cited by in F6Publishing: 1] [Reference Citation Analysis]